A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

NCT02065479 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Prasugrel
DRUG: Ticagrelor

Sponsor

University of Florida